Editorial
First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
Abstract
Molecular profiling in patients with newly diagnosed advanced non-small cell lung cancer (NSCLC) has become routine in clinical practice, allowing us to provide the most effective treatment to individuals harboring actionable genetic alterations.
